Unlike hyperglycemia-associated sodium channel activation that favors arrhythmogenesis, SGLT-2 inhibition leads to favorable ionic balance and sustained antiarrhythmic benefits in AF [67]. This evidence concerns the gene SLC5A2 and atrial fibrillation.